Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00209092 · ClinicalTrials.gov registry record · Phase 2
Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 19
- Study locations
NCT00209092: Completed Phase 2 study of Breast Cancer, sponsored by Emory University.
NCT00209092 is a Phase 2 study of Breast Cancer that has completed, run by Emory University. The registered enrollment target is 51 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 19 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00209092, a Phase 2 study of Breast Cancer, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
Primary Outcome
Pathologic complete response (pCR): Absence of invasive breast cancer in the breast. Overall Clinical Response=Complete response(CR-complete disappearance of all measurable malignant disease)+partial response(PR-reduction by at least 30%) Stable disease (SD): No decrease or \<25% increase in the sum of the products of the longest perpendicular diameters of all measurable lesions. Progressive disease (PD): A 20% or greater increase in a single lesion, OR reappearance of any lesion which has di
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Capecitabine
Study Locations (19)
Georgia
- Grady Memorial Hospital - Atlanta
- Emory Crawford Long Hospital - Atlanta
- Emory University Winship Cancer Institute - Atlanta
- Augusta Oncology Associates, PC 1348 Walton Way, Ste. 4300 - Augusta
- Augusta Oncology Associates, PC 3696 Wheeler Road - Augusta
- WellStar Health System-Georgia Cancer Specialists - Austell
- WellStar Health System-Northwest Georgia Oncology Center, PC - Austell
- WellStar Health System-Northwest Georgia Oncology Center, PC - Carrollton
- John B. Amos Cancer Center - Columbus
- Suburban Hematology-Oncology Associates, PC - Duluth
- South Atlanta Hematology-Oncology Group - East Point
- Suburban Hematology-Oncology Associates, PC - Lawrenceville
- Central Georgia Cancer Care, PC - Macon
- WellStar Health System-Georgia Cancer Specialists - Marietta
- WellStar Health System-Northwest Georgia Oncology Center, PC - Marietta
- South Atlanta Hematology-Oncology Group - Riverdale
- Suburban Hematology-Oncology Associates, PC - Snellville
- South Atlanta Hematology-Oncology Group - Stockbridge
- Central Georgia Cancer Care, PC - Warner Robins
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT00209092 record still lists
NCT00209092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT00209092 lists 19 locations in 1 state (Georgia).
Frequently Asked Questions
What is clinical trial NCT00209092 about?
NCT00209092 is a clinical study titled "Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer". The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
What is the current status of trial NCT00209092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2006-08. Estimated completion is 2012-10.
What conditions does trial NCT00209092 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00209092?
The interventions under investigation include: Docetaxel (DRUG), Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00209092?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00209092 being conducted?
This trial has 19 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00209092's enrollment target sits among peer trials
51 782nd of 1224 higher than 437 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia